FXM Clinical Research Miramar LLC
Welcome,         Profile    Billing    Logout  
 2 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Flores, Francisco
NCT04239391: Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)

Recruiting
3
150
US
Triferic, FPC
Rockwell Medical Technologies, Inc.
End Stage Renal Disease
08/23
11/23
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Active, not recruiting
3
1108
Europe, Canada, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
12/24
11/25
ASCEND-P, NCT05682326 / 2021-002013-34: Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric

Completed
3
4
Japan, RoW
Daprodustat
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited, GSK Research & Development Limited
Anaemia
03/25
03/25
NCT06633029: Retrospective Analysis of Prismaflex HF20 Set Versus ppCRRT Registry

Recruiting
N/A
106
US
Prismaflex HF20, Prismaflex M60
Baxter Healthcare Corporation
Acute Renal Failure (ARF), Acute Kidney Injury (AKI), Fluid Overload in Dialysis Patients
05/25
05/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Flores, Francisco
NCT04239391: Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)

Recruiting
3
150
US
Triferic, FPC
Rockwell Medical Technologies, Inc.
End Stage Renal Disease
08/23
11/23
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Active, not recruiting
3
1108
Europe, Canada, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
12/24
11/25
ASCEND-P, NCT05682326 / 2021-002013-34: Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric

Completed
3
4
Japan, RoW
Daprodustat
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited, GSK Research & Development Limited
Anaemia
03/25
03/25
NCT06633029: Retrospective Analysis of Prismaflex HF20 Set Versus ppCRRT Registry

Recruiting
N/A
106
US
Prismaflex HF20, Prismaflex M60
Baxter Healthcare Corporation
Acute Renal Failure (ARF), Acute Kidney Injury (AKI), Fluid Overload in Dialysis Patients
05/25
05/25

Download Options